Amyloid PET in AD, FTD & PPA
View as
Eligibility
- Inclusion criteria: Participants must be over the age of 50 and meet criteria for either frontotemporal dementia (FTD), Alzheimer's disease (AD), corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), amyotrophic lateral sclerosis (ALS) or healthy aging group. Patients are encouraged but not required to co-enroll in the Frontotemporal Dementia: Genes, Images and Emotions or New Approaches to Dementia Heterogeneity studies.
- Exclusion criteria: Participants cannot have a history of another major neurological disorder that could be a potential cause of dementia, active substance abuse, major systemic illnesses including active cancer, renal or liver failure, respiratory failure requiring oxygen, or use of current medications likely to affect the central nervous system (CNS). Patients are not eligible if they have had a nuclear imaging study (PET or SPECT) in the past year or are actively enrolled in an anti-amyloid clinical trial.
Article Image:
ftd/AmyloidPET.jpg
Featured Articles: